Index to Volume 307

AUTHORS

Abraham NG. *See* da Silva J-L
Adamkin DH. *See* Samiec TD
Adelman HM, Cacciatore ML, Pascual JF, Mike JM, Alberts WM, Wallach PM. Castleman Disease in Association With POEMS., 307(2):112–114.
Aguilar C. *See* McBride WS
Akema N. *See* Shionoiri H
Alberts WM. *See* Adelman HM
Altszuler HM. *See* Weinshel EH
Ambrosioni E. *See* Borghi C
Amery A. *See* Lijnen P
Anagnou N. *See* Lianos EA
Appalsamy M, Robertson D, Mosqueda-Garcia R. Inhibition by Ethanol of the Cardiovascular Effects of Glutamate in the Nucleus of the Solitary Tract., 307(2): 133–137.
Appel RG. *See* Stone HD
Araque A. *See* Ruilope LM
Arita T. *See* Shionoiri H
Asahina S. *See* Shionoiri H
Ashino K. *See* Shionoiri H
Asmar R. *See* Safar ME
Barbagallo M, Resnick LM. The Role of Glucose in Diabetic Hypertension: Effects on Intracellular Cation Metabolism., 307(S1). S60–S65
Barbagallo M. *See* Resnick LM
Barton JC. *See* Butler TW
Batlle DC. *See* LaPointe MS. *See also* Schlueter W
Bauman WA. *See* Kahn NN
Benetos A. *See* Safar ME
Berecek KH. *See* Oparil S
Berggren T. *See* Johnson JR
Bergmann C. *See* Gairard A
Berkow R. *See* Butler TW
Bernard GR. *See* Morris PE
Bernicker E. *See* Caldas C
Berry M. *See* Conrad ME
Betzing KW. *See* Bounds W
Bian K. *See* Li J
Boctor D. *See* Wolever TMS
Borghi C, Mussi A, Boschi S, Costa FV, Ambrosioni E. Relationship Between Acute Suppression of Plasma Renin Activity and Lymphocyte Na :H Exchange Rate in Young Patients With Borderline Hypertension., 307(S1). S159–S162
Boschi S. *See* Borghi C
Bounds W, Betzing KW, Stewart RM, Holcombe RF. Social Drinking and the Immune Response: Impairment of Lymphokine-Activated Killer Activity., 307(6):391–395.
Bower RH. *See* Lutomski DM
Brier ME, Luft FC. Sodium Kinetics in White and Black Normotensive Subjects: Possible Relevance to Salt-Sensitive Hypertension., 307(S1). S38–S42
Broughton G II. Chenodeoxycholate: The Bile Acid. The Drug. A Review., 307(1): 54–63.
Bukoski RD. *See* Li J
Bummer PM, Sanders LP, Pauly TH, Gillespie MN. In Vitro Inactivation of Pulmonary Surfactant Replacement Preparations by Serum Albumin., 307(6): 401–404.
Butler TW, Heck LW, Berkow R, Barton JC. Radioimmunometric Quantification of Surface Lactoferrin in Blood Mononuclear Cells., 307(2):102–107.
Cacciatore ML. *See* Adelman HM
Caldas C, Bernicker E, Nogare AD, Luby JP. Transverse Myelitis Associated With Epstein-Barr Virus Infection., 307(1):45–48.
Campbell VW, Davin D, Thomas S, Jones D, Roesel J, Tran-Patterson R, Mayfield CA, Rodu B, Miller DM, Hiramoto RA. The G-C Specific DNA Binding Drug, Mithramycin, Selectivity Inhibits Transcription of the C-MYC and C-HA-RAS Genes in Regenerating Liver., 307(3):167–172.
Carpenter C, May ME. Cardiotoxic Calcemia., 307(1):43–44.
Carr ME. *See* Greilich PE
Cattell V. *See* Lianos EA
Centurion OA, Shimizu A, Isomoto S, Konoe A, Hirata T, Hano O, Kaibara M, Yano K. Repetitive Atrial Firing and Fragmented Atrial Activity Elicited by Extrastimuli in the Sick Sinus Syndrome With and Without Abnormal Atrial Electrograms., 307(4):247–254.
Ceolotto G. *See* Semplicini A
Chabanis S. *See* Drüeke TB
Chao ESM. *See* Wolever TMS
Charles PD, Davis TL. Sumatriptan for Migraine., 307(6):445–447.
Chen SJ. *See* Oparil S
Cicco G. *See* Nazzaro P
Cicila G. *See* Hayzer DJ
Cockerham C. *See* Hayzer DJ
Collins KA. *See* Davda RK
Connell JMC. *See* Morris AD
Connolly M. *See* Zaim S
Conrad ME, Uzel C, Berry M, Latour L. Ironic Catastrophes: One's Food—Another's Poison., 307(6):434–437.
Cook T. *See* Lianos EA
Costa FV. *See* Borghi C
Craver J. *See* Zaim S
Dal Palù C. *See* Semplicini A
da Silva J-L, Tiefenthaler M, Park E, Escalante B, Schwartzman ML, Levere KD, Abraham NG. Tin-Mediated Heme Oxygenase Gene Activation and Cytochrome P450 Arachidonate Hydroxylase Inhibition in Spontaneously Hypertensive Rats., 307(3):173–181.
Dauber JH. *See* Maholtz MS
Davda RK, Collins KA, Kitchens CS. Fatal *Staphylococcus aureus* Sepsis From Single-Donor Platelet Transfusion., 307(5):340–341.
Davidson RA, Schwartz MD, Harris JO. Effect of a Simple Ambulatory Experience on Career Choice and Attitudes of Medical Students., 307(1):36–39.
Davin D. *See* Campbell VW
Davis JM, Sadasivan R, Dwyer T, Van Veldhuizen P. Cholangiocarcinoma and Hypercalcemia., 307(5):350–352.
Davis TL. *See* Charles PD
deBoisblanc BP. *See* Parker JS
Delafontaine P. *See* Hayzer DJ. *See also* Ververis J
DeMerritt JA. *See* Hatton DC
Dent RM. *See* Greilich PE
De Toni R. *See* Semplicini A
Distler A. *See* Sharma AM
Dover GJ. *See* Henderson RA
Drüeke TB, Chabanis S, Roullet C, Duchambon P, Lacour B, McCarron DA. Abnormal Regulation of Intestinal Calbindin (CaBP9k) and Calmodulin in the Spontaneously Hypertensive Rat., 307(S1). S96–S101
Drüeke TB, McCarron DA. Introduction: Paris Symposium., 307(S1). S1–S2
Duchambon P. *See* Drüeke TB
Dumas P, Tremblay J, Hamet P. Stress Modulation by Electrolytes in Salt-Sensitive Spontaneously Hypertensive Rats., 307(S1). S130–S137
Dwyer T. *See* Davis JM
Elion JL. *See* Santos-Ocampo CD
Escalante B. *See* da Silva J-L
Falletti D. *See* Piccirillo G
Fessler HE. *See* Terry PB
Fimognari FL. *See* Piccirillo G
Fimognari GB. *See* Piccirillo G
Floyd ME. *See* Hoffman RA
Fujishima M. *See* Koga H
Fulgoni V III. *See* Wolever TMS
Fusilli L. *See* Patel J
Gairard A, Pernot F, Bergmann C, Van Overloop B. Ions, Parathyroids, and Genetic Hypertension., 307(S1). S126–S129
Galluser M. *See* Schleiffer R

Garay R, Senn N, Ollivier J-P. Erythrocyte Ion Transport as Indicator of Sensitivity to Antihypertensive Drugs., 307(S1). S120–S125
Garber CE. *See* Santos-Ocampo CD
Germain M, Gourdeau M, Hébert J. Familial Chronic Mucocutaneous Candidiasis Complicated by Deep Candida Infection., 307(4):282–283.
Gholson CF, Sittig K, McDonald JC. Recent Advances in the Management of Gallstones., 307(4):293–304.
Gilchrist IC, Waksman DG, Herr MD, McInerney JJ. Real-time Ventricular Volumes and Cardiac Function in the Working Rat Heart., 307(2):92–96.
Gillespie MN. *See* Bummer PM
Glueck CJ, Glueck HI, Hamer T, Speirs J, Tracy T, Stroop D. Beta Blockers, Lp(a), Hypertension, and Reduced Basal Fibrinolytic Activity., 307(5):317–324.
Glueck HI. *See* Glueck CJ
Gonick HC. *See* Weiler EWJ
Gotoh E. *See* Shionoiri H
Gourdeau M. *See* Germain M
Granger DN. *See* Zimmerman BJ
Grayburn PA. Clinical Applications of Transesophageal Echocardiography., 307(2):151–161.
Greilich PE, Carr ME, Zekert SL, Dent RM. Quantitative Assessment of Platelet Function and Clot Structure in Patients With Severe Coronary Artery Disease., 307(1):15–20.
Griendling KK. *See* Hayzer DJ
Grobbee DE. Electrolytes and Hypertension: Results From Recent Studies., 307(S1). S17–S20
Grubb BP. *See* Samoil D
Gupta RK. *See* Resnick LM
Hamer T. *See* Glueck CJ
Hamet P. *See* Dumas P
Hand R, Piontek F, Klemka-Walden L, Inczauskis D. Use of Statistical Control Charts to Assess Outcomes of Medical Care: Pneumonia in Medicare Patients., 307(5):329–334.
Hano O. *See* Centurion OA
Harford WV. The Syndrome of Angina Pectoris: Role of Visceral Pain Perception., 307(4):305–315.
Harris JO. *See* Davidson RA
Hata T. *See* Shionoiri H
Hatchell DL. *See* Kirkman MS
Hatton DC, Xue H, DeMerritt JA, McCarron DA. 1,25(OH)2 Vitamin D3-Induced Alterations in Vascular Reactivity in the Spontaneously Hypertensive Rat., 307(S1). S154–S158
Hayzer DJ, Cicila G, Cockerham C, Griendling KK, Delafontaine P, Ng SC, Runge MS. Endothelin A and B Receptors Are Down-Regulated in the Hearts of Hypertensive Rats., 307(3):222–227.
Hébert J. *See* Germain M
Heck LW. *See* Butler TW
Henderson RA, Saavedra JM, Dover GJ. Prevalence of Impaired Growth in Children With Homozygous Sickle Cell Anemia., 307(6):405–407.
Henle KJ. *See* Mansouri A
Herr MD. *See* Gilchrist IC
Higuma K. *See* Shionoiri H
Hill T. *See* Samiec TD
Hirakata H. *See* Koga H
Hiramoto RA. *See* Campbell VW
Hirata T. *See* Centurion OA
Hoffman RA, Fioyd ME, Whetsell LH, Kramer JC, Schaefer FV. Cystic Fibrosis in the Southern Midwest United States: Molecular Characterization of the Common Mutations., 307(2):82–85.
Holcombe RF. *See* Bounds W
Holuoka J. *See* Sarmiento R
Hsia CCW. Pulmonary Complications of High-Altitude Exposure., 307(6):448–464.
Iimura O. *See* Shimamoto K
Ikegami H. *See* Shionoiri H
Inczauskis D. *See* Hand R
Infantino V. *See* Piccirillo G
Ishida I. *See* Koga H
Ishii M. *See* Shionoiri H
Isomoto S. *See* Centurion OA
Ito T. *See* Shionoiri H
Iwatsubo H. *See* Shionoiri H
Jackson JG. *See* Yee D
Jacobs RA. *See* Tokumoto JIN
Jenkins DJA. *See* Wolever TMS
Jin HG. *See* Oparil S
Johnson JR, Berggren T. Pigeon and Dove Eggwhite Protect Mice Against Renal Infection Due to P Fimbriated *Escherichia coli.*, 307(5):335–339.
Jones D. *See* Campbell VW
Jones E. *See* Zaim S
Kachelhoffer J. *See* Schleiffer R
Kahn NN, Bauman WA, Sinha AK. Transient Decrease of Binding of Insulin to Platelets in Acute Ischemic Heart Disease., 307(1):21–26.
Kaibara M. *See* Centurion OA
Katahira K. *See* Shionoiri H
Katzman Relle L. *See* Wolever TMS
Kawaguchi Y. *See* Shionoiri H
Keilani T. *See* Schlueter W
Kerins DM. Role of the Perfluorocarbon Fluosal-DA in Coronary Angioplasty., 307(3):218–221.
Kern PA, Trozzolino L, Wolfe G, Purdy L. Combined Use of Behavior Modification and Very Low-Calorie Diet in Weight Loss and Weight Maintenance., 307(5):325–328.
Khanna A, Naik SR, Thyagarajan SP, Talwar GP, Ray R. Seroreactivity and Genomic Amplification Profile of Hepatitis C Virus From Patients With Chronic Liver Disease in India., 307(2):144–150.
Khatib R. *See* Sarmiento R
Kirkman MS, Simel DL, Rao KMK, Hatchell DL. Granulocyte Deformability and F-Actin Content: Relationship to Diabetes Mellitus and Retinopathy., 307(2):86–91.
Kitchens CS. *See* Davda RK
Klemka-Walden L. *See* Hand R
Koga H, Oochi N, Osato S, Ishida I, Hirakata H, Okuda S, Fujishima M. Wegener's Granulomatosis Accompanied by Communicating Hydrocephalus., 307(4):278–281.
Kolloch R. *See* Ruppert M
Konoe A. *See* Centurion OA
Kraft K. *See* Ruppert M
Kramer JC. *See* Hoffman RA
Krantz SB. Pathogenesis and Treatment of the Anemia of Chronic Disease., 307(5):353–359.
Krishna GG. Role of Potassium in the Pathogenesis of Hypertension., 307(S1). S21–S25
Ku L. *See* Ververis J
Kumar R. *See* Raj G
Kumar V. *See* Wortsman J
Lacour B. *See* Drüeke TB
Lahera V. *See* Ruilope LM
LaPointe MS, Batlle DC. Na /H Exchange and Vascular Smooth Muscle Proliferation., 307(S1). S9–S16
Laragh JH. *See* Resnick LM
Latour L. *See* Conrad ME
Lee W. *See* Patel J
Lennarz M. *See* Ruppert M
Levere RD. *See* da Silva J-L
Levine SP. *See* Peacock NW
Levy BI. *See* Safar ME
Lianos EA, Orphanos V, Cattell V, Cook T, Anagnou N. Glomerular Expression and Cell Origin of Transforming Growth Factor-β1 in Anti-Glomerular Basement Membrane Disease., 307(1):1–6.
Li J, Bian K, Bukoski RD. A Non-Cyclo-Oxygenase, Non-Nitric Oxide Relaxing Factor is Present in Resistance Arteries of Normotensive but not Spontaneously Hypertensive Rats., 307(1):7–14.
Lijnen P, Petrov V, Amery A. Relationship Between Erythrocyte Cation Transport Systems and Membrane and Plasma Lipids in Healthy Men., 307(S1). S146–S149
London GM. *See* Safar ME
Luby JP. *See* Caldas C
Luft FC. *See* Brier ME
Lutomski DM, Bower RH. The Effect of Thrombocytosis on Serum Potassium and Phosphorus Concentrations., 307(4):255–258.
Mack KD, Walzem R, Zeldis JB. Cationic Lipid Enhances in Vitro Receptor-Mediated Transfection., 307(2):138–143.
Maholtz MS, Dauber JH, Yousem SA. Fluconazole Therapy in Histoplasma Mediastinal Granuloma., 307(4):274–277.
Malone LL. *See* Santos-Ocampo CD
Mancini M. *See* Strazzullo P
Mansouri A, Henle KJ, Nagle WA. Tumor Drug-Resistance: A Challenge to Therapists and Biologists., 307(6):438–444.
Manzari M. *See* Nazzaro P
Marigliano V. *See* Piccirillo G
Massimino M. *See* Semplicini A
Mayfield CA. *See* Campbell VW
May ME. *See* Carpenter C
McBride WS, Mulrow CD, Aguilar C,

Tuley MR. Methods for Screening for Hearing Loss in Older Adults., 307(1):40–42.
McCarron DA. *See* Drüeke TB
McCarron DA. *See* Hatton DC
McCombs CC. *See* Michalski JP
McDonald JC. *See* Gholson CF
McInerney JJ. *See* Gilchrist IC
McKinney WP. *See* Raj G
Mcmillan K. *See* Wolever TMS
Meidell RS. Endothelial Dysfunction and Vascular Disease., 307(5):378–389.
Meng QC. *See* Oparil S
Merlo M. *See* Nazzaro P
Merrick RD, Vernon M. The Anticardiolipin (Antibody) Syndrome., 307(6):414–417.
Michalski JP, McCombs CC. Celiac Disease: Clinical Features and Pathogenesis., 307(3):204–211.
Mikami H. *See* Shionoiri H
Mike JM. *See* Adelman HM
Miller DM. *See* Campbell VW
Miyazaki N. *See* Shionoiri H
Monteleone G. *See* Piccirillo G
Morris AD, Connell JMC. Insulin Resistance and Essential Hypertension: Mechanisms and Clinical Implications., 307(S1). S47–S52
Morris PE, Bernard GR. Significance of Glutathione in Lung Disease and Implications for Therapy., 307(2):119–127.
Mosqueda-Garcia R. *See* Appalsamy M
Mudoni A. *See* Nazzaro P
Mueller S. *See* Wolever TMS
Mulrow CD. *See* McBride WS
Mussi A. *See* Borghi C
Nagle WA. *See* Mansouri A
Naik SR. *See* Khanna A
Nakamura M, Suzuki H, Yamakawa H, Ohno Y, Saruta T. Calcium Restriction Accelerates Salt-Induced Hypertension in Young Spontaneously Hypertensive Rats., 307(S1). S138–S141
Nazzaro P, Merlo M, Manzari M, Mudoni A, Cicco G, Pirrelli A. Diabetes Modifies Cardiovascular Reactivity During Hypertension., 307(S1). S142–S145
Nazzaro P, Cicco G, Manzari M, Merlo M, Pirrelli A. Lipids and Cardiovascular Reactivity Changes in Hypertensive Cigarette Smokers: Enalapril Versus Nifedipine Treatment Effects., 307(S1). S150–S153
Neuzil KM. Pharmacologic Therapy for Human Immunodeficiency Virus Infection: A Review., 307(5):368–373.
Ng SC. *See* Hayzer DJ
Nishimura M. *See* Shimamoto K
Nogare AD. *See* Caldas C
O'Dorisio TM. *See* Schuster D
Ogihara T. *See* Shionoiri H
Ohno Y. *See* Nakamura M
Okuda S. *See* Koga H
Ollivier J-P. *See* Garay R
Oochi N. *See* Koga H
Oparil S, Yang RH, Jin HG, Chen SJ, Meng QC, Berecek KH, Wyss JM. Role of Anterior Hypothalamic Angiotensin II in the Pathogenesis of Salt Sensitive Hypertension in the Spontaneously Hypertensive Rat., 307(S1). S26–S37
Orphanos V. *See* Lianos EA
Osato S. *See* Koga H
Osei K. *See* Schuster D
Otsuka A. *See* Shionoiri H
Overlack A. *See* Ruppert M
Parisi AF. *See* Santos-Ocampo CD
Park E. *See* da Silva J-L
Parker JS, deBoisblanc BP. Actinomycosis: Multinodular Pulmonary Involvement., 307(6):418–419.
Parrino NF. *See* Parrino TA
Parrino TA, Parrino NF. The Acquisition of Practical Skills by U.S. Medical Students., 307(3):163–166.
Pascual JF. *See* Adelman HM
Patel J, Lee W, Fusilli L, Regan TJ. Anti-Arrhythmic Efficacy of Beta-Adrenergic Blockade During Acute Ischemia in Myocardium With Scar., 307(4):259–263.
Patten R. *See* Wolever TMS
Pauly TH. *See* Bummer PM
Peacock NW, Levine SP. The Lupus Anticoagulant-Hypoprothrombinemia Syndrome., 307(5):346–349.
Pernot F. *See* Gairard A
Pessina AC. *See* Semplicini A
Petrov V. *See* Lijnen P
Piccirillo G, Fimognari FL, Infantino V, Monteleone G, Fimognari GB, Falletti D, Marigliano V. High Plasma Concentrations of Cortisol and Thromboxane B_2 in Patients With Depression., 307(3):228–232.
Piontek F. *See* Hand R
Pirrelli A. *See* Nazzaro P
Prins BA. *See* Weiler EWJ
Purdy L. *See* Kern PA
Purdy RE. *See* Weiler EWJ
Radmacher P. *See* Samiec TD
Radolf JD. Brucellosis: Don't Let it Get Your Goat., 307(1):64–75.
Raicht RF. *See* Weinshel EH
Raj G, Kumar R, McKinney WP. Long-term Oral Anticoagulant Therapy: Update on Indications, Therapeutic Ranges, and Monitoring., 307(2):128–132.
Ramwell PW. *See* Thomas G
Ransom TPP. *See* Wolever TMS
Rao KMK. *See* Kirkman MS
Raul F. *See* Schleiffer R
Ravdin PM. *See* Yee D
Ray R. *See* Khanna A
Regan TJ. *See* Patel J
Resnick LM, Gupta RK, Barbagallo M, Laragh JH. Is the Higher Incidence of Ischemic Disease in Patients With Hypertension and Diabetes Related to Intracellular Depletion of High Energy Metabolites?., 307(S1). S66–S69
Resnick LM. *See* Barbagallo M
Robertson D. *See* Appalsamy M
Rocchini AP. The Relationship of Sodium Sensitivity to Insulin Resistance., 307(S1). S75–S80
Rodicio JL. *See* Ruilope LM
Rodu B. *See* Campbell VW
Roesel J. *See* Campbell VW
Roman-Gonzalez J. *See* Zaim S
Romero JC. *See* Ruilope LM
Roullet C. *See* Drüeke TB
Ruilope LM, Lahera V, Araque A, Suarez C, Rodicio JL, Romero JC. Electrolyte Excretion and Sodium Intake., 307(S1). S107–S111
Runge MS. *See* Hayzer DJ
Ruppert M, Overlack A, Kolloch R, Kraft K, Lennarz M, Stumpe KO. Effects of Severe and Moderate Salt Restriction on Serum Lipids in Nonobese Normotensive Adults., 307(S1). S87–S90
Saavedra JM. *See* Henderson RA
Sadaniantz A. *See* Santos-Ocampo CD
Sadasivan R. *See* Davis JM
Safar ME, Asmar R, Benetos A, Levy BI, London GM. Sodium, Large Arteries, and Diuretic Compounds in Hypertension., 307(S1). S3–S8
Samiec TD, Radmacher P, Hill T, Adamkin DH. Measured Energy Expenditure in Mechanically Ventilated Very Low Birth Weight Infants., 307(3): 182–184.
Samoil D, Grubb BP, Temesy-Armos PN. Sotalol: A New Agent for the Treatment of Ventricular Arrhythmias., 307(1): 49–53.
Sanders LP. *See* Bummer PM
Santos-Ocampo CD, Sadaniantz A, Elion JL, Garber CE, Malone LL, Parisi AF. Echocardiographic Assessment of the Cardiac Anatomy in Patients With Multifocal Atrial Tachycardia: A Comparison With Atrial Fibrillation., 307(4):264–268.
Sarmiento R, Holubka J, Khatib R. Candida Meningitis With an Intradural Filling Defect 1 Year After Candidemia., 307(2):115–118.
Saruta T. *See* Nakamura M
Schaefer FV. *See* Hoffman RA
Schleiffer R, Galluser M, Kachelhoffer J, Raul F. Dietary Calcium Supplementation, Blood Pressure, and Intestinal Calcium Absorption., 307(S1). S116–S119
Schlueter W, Keilani T, Batlle DC. Tissue Renin Angiotensin Systems: Theoretical Implications for the Development of Hyperkalemia Using Angiotensin-Converting Enzyme Inhibitors., 307(S1). S81–S86
Schuster D, O'Dorisio TM, Osei K. Defective Beta and Alpha Cell Regulation in Patients With Hyperinsulinemia and Acanthosis Nigricans., 307(5):342–345.
Schwartzman ML. *See* da Silva J-L
Schwartz MD. *See* Davidson RA
Sedlis SP. *See* Weinshel EH
Semplicini A, Ceolotto G, Massimino M, Valle R, Serena L, De Toni R, Pessina AC, Dal Palù C. Interactions Between Insulin and Sodium Homeostasis in Essential Hypertension., 307(S1). S43–S46
Senn N. *See* Garay R

Serena L. *See* Semplicini A
Sharma AM, Distler A. Acid-Base Abnormalities in Hypertension., 307(S1). S112–S115
Shimamoto K, Ura N, Nishimura M, Iimura O. Renal Kallikrein-Kinin, Prostaglandin E2, and Dopamine Systems in Young Normotensive Subjects With a Family History of Essential Hypertension., 307(S1). S70–S74
Shimizu A. *See* Centurion OA
Shionoiri H, Gotoh E, Ito T, Hata T, Iwatsubo H, Takegawa K, Ogihara T, Mikami H, Ikegami H, Otsuka A, Katahira K, Kawaguchi Y, Arita T, Higuma K, Asahina S, Ashino K, Miyazaki N, Akema N, Ishii M. Long-Term Therapy With Terazosin May Improve Glucose and Lipid Metabolism in Hypertensives: A Multicenter Prospective Study., 307(S1). S91–S95
Simel DL. *See* Kirkman MS
Sinha AK. *See* Kahn NN
Sittig K. *See* Gholson CF
Speirs J. *See* Glueck CJ
Stein RS. Clinical Use of Growth Factors in the Myelodysplastic Syndromes., 307(5):360–367.
Stewart RM. *See* Bounds W
Stone HD, Appel RG. Human Immunodeficiency Virus-Associated Nephropathy: Current Concepts., 307(3):212–217.
Strazzullo P, Mancini M. Hypertension, Calcium Metabolism, and Nephrolithiasis., 307(S1). S102–S106
Stroop D. *See* Glueck CJ
Stumpe KO. *See* Ruppert M
Suarez C. *See* Ruilope LM
Suzuki H. *See* Nakamura M
Swartz RP. *See* Thomas G
Takegawa K. *See* Shionoiri H
Talwar GP. *See* Khanna A
Temesy-Armos PN. *See* Samoil D
Terry PB, Fessler HE. Should Intensive Care Be Limited for Patients With Self-Induced Disease?., 307(5):374–377.
Thomas G, Swartz RP, Yeager H Jr, Ramwell PW. Human Alveolar Macrophage Mediated Vasodilation and the Role of Arginine Compounds., 307(6): 408–413.
Thomas S. *See* Campbell VW
Thyagarajan SP. *See* Khanna A
Tiefenthaler M. *See* da Silva J-L
Tokumoto JIN, Jacobs RA. *Nocardia* Osteomyelitis., 307(6):428–433.
Tracy T. *See* Glueck CJ
Tran-Patterson R. *See* Campbell VW
Tremblay J. *See* Dumas P
Trozzolino L. *See* Kern PA
Tuley MR. *See* McBride WS
Ura N. *See* Shimamoto K
Uzel C. *See* Conrad ME
Valle R. *See* Semplicini A
Van Overloop B. *See* Gairard A
Van Veldhuizen P. *See* Davis JM
Vernon M. *See* Merrick RD
Ververis J, Ku L, Delafontaine P. Fibroblast Growth Factor Regulates Insulin-like Growth Factor-Binding Protein Production by Vascular Smooth Muscle Cells., 307(2):77–81.
Von Hoff DD. *See* Yee D
Waksman DG. *See* Gilchrist IC
Wallach PM. *See* Adelman HM
Walter P. *See* Zaim S
Walzem R. *See* Mack KD
Weber MA. *See* Weiler EWJ
Weder AB. Sodium Metabolism, Hypertension, and Diabetes., 307(S1). S53–S59
Weiler EWJ, Gonick HC, Prins BA, Purdy RE, Weber MA. Characterization of a Low Molecular Weight Na-K-ATPase Inhibitor of Urinary Origin., 307(1):27–35.
Weinshel EH, Altszuler HM, Raicht RF, Sedlis SP. Beta Adrenergic Stimulation and Blockade in Cirrhosis: Effects on Azygos Vein Blood Flow and Portal Hemodynamics., 307(6):396–400.
Weissler JC. Sarcoidosis: Immunology and Clinical Management., 307(3):233–245.
Whetsell LH. *See* Hoffman RA
Wolever TMS. Effect of Meal Frequency on Serum Amino Acids and Creatinine Clearance in Young Men., 307(2):97–101.
Wolever TMS, Jenkins DJA, Mueller S, Patten R, Katzman Relle L, Boctor D, Ransom TPP, Chao ESM, Mcmillan K, Fulgoni V III. Psyllium Reduces Blood Lipids in Men and Women With Hyperlipidemia., 307(4):269–273.
Wolfe G. *See* Kern PA
Wortsman J, Kumar V. Idiopathic Hypoparathyroidism Co-Existing With Celiac Disease: Immunologic Studies., 307(6):420–427.
Wyss JM. *See* Oparil S
Xue H. *See* Hatton DC
Yamakawa H. *See* Nakamura M
Yang RH. *See* Oparil S
Yano K. *See* Centurion OA
Yawata Y. Band 4.2 Abnormalities in Human Red Cells., 307(3):190–203.
Yeager H Jr. *See* Thomas G
Yee D, Jackson JG, Von Hoff DD, Ravdin PM. Use of Insulin-like Growth Factor-I Gene Expression to Distinguish Between Breast and Ovarian Cancer., 307(2):108–111.
Yousem SA. *See* Maholtz MS
Zaim S, Connolly M, Roman-Gonzalez J, Walter P, Craver J, Jones E. Perioperative Complications of Cardioverter-Defibrillator Implantation: The Emory Experience., 307(3):185–189.
Zekert SL. *See* Greilich PE
Zeldis JB. *See* Mack KD
Zimmerman BJ, Granger DN. Mechanisms of Reperfusion Injury., 307(4):284–292.

TITLES

A Non-Cyclo-Oxygenase, Non-Nitric Oxide Relaxing Factor is Present in Resistance Arteries of Normotensive but not Spontaneously Hypertensive Rats. Li J, Bian K, Bukoski RD., 307(1): 7–14.
Abnormal Regulation of Intestinal Calbindin (CaBP9k) and Calmodulin in the Spontaneously Hypertensive Rat. Drüeke TB, Chabanis S, Roullet C, Duchambon P, Lacour B, McCarron DA., 307(S1):**S96–S101**
Acid-Base Abnormalities in Hypertension. Sharma AM, Distler A., 307(S1): **S112–S115**
Anti-Arrhythmic Efficacy of Beta-Adrenergic Blockade During Acute Ischemia in Myocardium With Scar. Patel J, Lee W, Fusilli L, Regan TJ., 307(4):259–263.
Beta Adrenergic Stimulation and Blockade in Cirrhosis: Effects on Azygos Vein Blood Flow and Portal Hemodynamics. Weinshel EH, Altszuler HM, Raicht RF, Sedlis SP., 307(6): 396–400.
Beta Blockers, Lp(a), Hypertension, and Reduced Basal Fibrinolytic Activity. Glueck CJ, Glueck HI, Hamer T, Speirs J, Tracy T, Stroop D., 307(5):317–324.
Calcium Restriction Accelerates Salt-Induced Hypertension in Young Spontaneously Hypertensive Rats. Nakamura M, Suzuki H, Yamakawa H, Ohno Y, Saruta T., 307(S1):**S138–S141**
Characterization of a Low Molecular Weight Na-K-ATPase Inhibitor of Urinary Origin. Weiler EWJ, Gonick HC, Prins BA, Purdy RE, Weber MA., 307(1):27–35.
Combined Use of Behavior Modification and Very Low-Calorie Diet in Weight Loss and Weight Maintenance. Kern PA, Trozzolino L, Wolfe G, Purdy L., 307(5):325–328.
Cystic Fibrosis in the Southern Midwest United States: Molecular Characterization of the Common Mutations. Hoffman RA, Floyd ME, Whetsell LH, Kramer JC, Schaefer FV., 307(2):82–85.
Diabetes Modifies Cardiovascular Reactivity During Hypertension. Nazzaro P, Merlo M, Manzari M, Mudoni A, Cicco G, Pirrelli A., 307(S1):**S142–S145**
Dietary Calcium Supplementation, Blood Pressure, and Intestinal Calcium Absorption. Schleiffer R, Galluser M, Kachelhoffer J, Raul F., 307(S1): **S116–S119**
Echocardiographic Assessment of the Cardiac Anatomy in Patients With Multifocal Atrial Tachycardia: A Comparison With Atrial Fibrillation. Santos-Ocampo CD, Sadaniantz A, Elion JL, Garber CE, Malone LL, Parisi AF., 307(4):264–268.
Effect of a Simple Ambulatory Experience on Career Choice and Attitudes of Medical Students. Davidson RA, Schwartz MD, Harris JO., 307(1):36–39.

Effect of Meal Frequency on Serum Amino Acids and Creatinine Clearance in Young Men. Wolever TMS., 307(2):97–101.

Effects of Severe and Moderate Salt Restriction on Serum Lipids in Nonobese Normotensive Adults. Ruppert M, Overlack A, Kolloch R, Kraft K, Lennarz M, Stumpe KO., 307(S1):**S87–S90**

Electrolyte Excretion and Sodium Intake. Ruilope LM, Lahera V, Araque A, Suarez C, Rodicio JL, Romero JC., 307(S1):**S107–S111**

Electrolytes and Hypertension: Results From Recent Studies. Grobbee DE., 307(S1):**S17–S20**

Erythrocyte Ion Transport as Indicator of Sensitivity to Antihypertensive Drugs. Garay R, Senn N, Ollivier J-P., 307(S1):**S120–S125**

Fibroblast Growth Factor Regulates Insulin-like Growth Factor-Binding Protein Production by Vascular Smooth Muscle Cells. Ververis J, Ku L, Delafontaine P., 307(2):77–81.

Glomerular Expression and Cell Origin of Transforming Growth Factor-β1 in Anti-Glomerular Basement Membrane Disease. Lianos EA, Orphanos V, Cattell V, Cook T, Anagnou N., 307(1): 1–6.

Granulocyte Deformability and F-Actin Content: Relationship to Diabetes Mellitus and Retinopathy. Kirkman MS, Simel DL, Rao KMK, Hatchell DL., 307(2):86–91.

Human Alveolar Macrophage Mediated Vasodilation and the Role of Arginine Compounds. Thomas G, Swartz RP, Yeager H Jr, Ramwell PW., 307(6): 408–413.

Hypertension, Calcium Metabolism, and Nephrolithiasis. Strazzullo P, Mancini M., 307(S1):**S102–S106**

In Vitro Inactivation of Pulmonary Surfactant Replacement Preparations by Serum Albumin. Bummer PM, Sanders LP, Pauly TH, Gillespie MN., 307(6):401–404.

Insulin Resistance and Essential Hypertension: Mechanisms and Clinical Implications. Morris AD, Connell JMC., 307(S1):**S47–S52**

Interactions Between Insulin and Sodium Homeostasis in Essential Hypertension. Semplicini A, Ceolotto G, Massimino M, Valle R, Serena L, De Toni R, Pessina AC, Dal Palù C., 307(S1): **S43–S46**

Introduction: Paris Symposium. Drüeke TB, McCarron DA., 307(S1):**S1–S2**

Ions, Parathyroids, and Genetic Hypertension. Gairard A, Pernot F, Bergmann C, Van Overloop B., 307(S1): **S126–S129**

Is the Higher Incidence of Ischemic Disease in Patients With Hypertension and Diabetes Related to Intracellular Depletion of High Energy Metabolites?. Resnick LM, Gupta RK, Barbagallo M, Laragh JH., 307(S1):**S66–S69**

Lipids and Cardiovascular Reactivity Changes in Hypertensive Cigarette Smokers: Enalapril Versus Nifedipine Treatment Effects. Nazzaro P, Cicco G, Manzari M, Merlo M, Pirrelli A., 307(S1):**S150–S153**

Long-Term Therapy With Terazosin May Improve Glucose and Lipid Metabolism in Hypertensives: A Multicenter Prospective Study. Shionoiri H, Gotoh E, Ito T, Hata T, Iwatsubo H, Takegawa K, Ogihara T, Mikami H, Ikegami H, Otsuka A, Katahira K, Kawaguchi Y, Arita T, Higuma K, Asahina S, Ashino K, Miyazaki N, Akema N, Ishii M., 307(S1):**S91–S95**

Measured Energy Expenditure in Mechanically Ventilated Very Low Birth Weight Infants. Samiec TD, Radmacher P, Hill T, Adamkin DH., 307(3):182–184.

Methods for Screening for Hearing Loss in Older Adults. McBride WS, Mulrow CD, Aguilar C, Tuley MR., 307(1):40–42.

Na /H Exchange and Vascular Smooth Muscle Proliferation. LaPointe MS, Batlle DC., 307(S1):**S9–S16**

1,25(OH)2 Vitamin D3-Induced Alterations in Vascular Reactivity in the Spontaneously Hypertensive Rat. Hatton DC, Xue H, DeMerritt JA, McCarron DA., 307(S1):**S154–S158**

Perioperative Complications of Cardioverter-Defibrillator Implantation: The Emory Experience. Zaim S, Connolly M, Roman-Gonzalez J, Walter P, Craver J, Jones E., 307(3):185–189.

Pigeon and Dove Eggwhite Protect Mice Against Renal Infection Due to P Fimbriated *Escherichia coli*. Johnson JR, Berggren T., 307(5):335–339.

Prevalence of Impaired Growth in Children With Homozygous Sickle Cell Anemia. Henderson RA, Saavedra JM, Dover GJ., 307(6):405–407.

Psyllium Reduces Blood Lipids in Men and Women With Hyperlipidemia. Wolever TMS, Jenkins DJA, Mueller S, Patten R, Katzman Relle L, Boctor D, Ransom TPP, Chao ESM, Mcmillan K, Fulgoni V III., 307(4):269–273.

Quantitative Assessment of Platelet Function and Clot Structure in Patients With Severe Coronary Artery Disease. Greilich PE, Carr ME, Zekert SL, Dent RM., 307(1):15–20.

Radioimmunometric Quantification of Surface Lactoferrin in Blood Mononuclear Cells. Butler TW, Heck LW, Berkow R, Barton JC., 307(2):102–107.

Real-time Ventricular Volumes and Cardiac Function in the Working Rat Heart. Gilchrist IC, Waksman DG, Herr MD, McInerney JJ., 307(2):92–96.

Relationship Between Erythrocyte Cation Transport Systems and Membrane and Plasma Lipids in Healthy Men. Lijnen P, Petrov V, Amery A., 307(S1):**S146–S149**

Relationship Between Acute Suppression of Plasma Renin Activity and Lymphocyte Na :H Exchange Rate in Young Patients With Borderline Hypertension. Borghi C, Mussi A, Boschi S, Costa FV, Ambrosioni E., 307(S1): **S159–S162**

Renal Kallikrein-Kinin, Prostaglandin E2, and Dopamine Systems in Young Normotensive Subjects With a Family History of Essential Hypertension. Shimamoto K, Ura N, Nishimura M, Iimura O., 307(S1):**S70–S74**

Repetitive Atrial Firing and Fragmented Atrial Activity Elicited by Extrastimuli in the Sick Sinus Syndrome With and Without Abnormal Atrial Electrograms. Centurion OA, Shimizu A, Isomoto S, Konoe A, Hirata T, Hano O, Kaibara M, Yano K., 307(4): 247–254.

Role of Anterior Hypothalamic Angiotensin II in the Pathogenesis of Salt Sensitive Hypertension in the Spontaneously Hypertensive Rat. Oparil S, Yang RH, Jin HG, Chen SJ, Meng QC, Berecek KH, Wyss JM., 307(S1):**S26–S37**

Role of Potassium in the Pathogenesis of Hypertension. Krishna GG., 307(S1): **S21–S25**

Social Drinking and the Immune Response: Impairment of Lymphokine-Activated Killer Activity. Bounds W, Betzing KW, Stewart RM, Holcombe RF., 307(6):391–395.

Sodium Kinetics in White and Black Normotensive Subjects: Possible Relevance to Salt-Sensitive Hypertension. Brier ME, Luft FC., 307(S1): **S38–S42**

Sodium Metabolism, Hypertension, and Diabetes. Weder AB., 307(S1):**S53–S59**

Sodium, Large Arteries, and Diuretic Compounds in Hypertension. Safar ME, Asmar R, Benetos A, Levy BI, London GM., 307(S1):**S3–S8**

Stress Modulation by Electrolytes in Salt-Sensitive Spontaneously Hypertensive Rats. Dumas P, Tremblay J, Hamet P., 307(S1):**S130–S137**

The Acquisition of Practical Skills by U.S. Medical Students. Parrino TA, Parrino NF., 307(3):163–166.

The Effect of Thrombocytosis on Serum Potassium and Phosphorus Concentrations. Lutomski DM, Bower RH., 307(4):255–258.

The G-C Specific DNA Binding Drug, Mithramycin, Selectivity Inhibits Transcription of the C-MYC and C-HA-RAS Genes in Regenerating Liver. Campbell VW, Davin D, Thomas S, Jones D, Roesel J, Tran-Patterson R,

Mayfield CA, Rodu B, Miller DM, Hiramoto RA., 307(3):167–172.

The Relationship of Sodium Sensitivity to Insulin Resistance. Rocchini AP., 307(S1):**S75–S80**

The Role of Glucose in Diabetic Hypertension: Effects on Intracellular Cation Metabolism. Barbagallo M, Resnick LM., 307(S1):**S60–S65**

Tin-Mediated Heme Oxygenase Gene Activation and Cytochrome P450 Arachidonate Hydroxylase Inhibition in Spontaneously Hypertensive Rats. da Silva J-L, Tiefenthaler M, Park E, Escalante B, Schwartzman ML, Levere RD, Abraham NG., 307(3):173–181.

Tissue Renin Angiotensin Systems: Theoretical Implications for the Development of Hyperkalemia Using Angiotensin-Converting Enzyme Inhibitors. Schlueter W, Keilani T, Batlle DC., 307(S1):**S81–S86**

Transient Decrease of Binding of Insulin to Platelets in Acute Ischemic Heart Disease. Kahn NN, Bauman WA, Sinha AK., 307(1):21–26.

Use of Statistical Control Charts to Assess Outcomes of Medical Care: Pneumonia in Medicare Patients. Hand R, Piontek F, Klemka-Walden L, Inczauskis D., 307(5):329–334.

Case Reports

Actinomycosis: Multinodular Pulmonary Involvement. Parker JS, deBoisblanc BP., 307(6):418–419.

Candida Meningitis With an Intradural Filling Defect 1 Year After Candidemia. Sarmiento R, Holubka J, Khatib R., 307(2):115–118.

Cardiotoxic Calcemia. Carpenter C, May ME., 307(1):43–44.

Castleman Disease in Association With POEMS. Adelman HM, Cacciatore ML, Pascual JF, Mike JM, Alberts WM, Wallach PM., 307(2):112–114.

Cholangiocarcinoma and Hypercalcemia. Davis JM, Sadasivan R, Dwyer T, Van Veldhuizen P., 307(5):350–352.

Defective Beta and Alpha Cell Regulation in Patients With Hyperinsulinemia and Acanthosis Nigricans. Schuster D, O'Dorisio TM, Osei K., 307(5):342–345.

Familial Chronic Mucocutaneous Candidiasis Complicated by Deep Candida Infection. Germain M, Gourdeau M, Hébert J., 307(4):282–283.

Fatal *Staphylococcus aureus* Sepsis From Single-Donor Platelet Transfusion. Davda RK, Collins KA, Kitchens CS., 307(5):340–341.

Fluconazole Therapy in Histoplasma Mediastinal Granuloma. Maholtz MS, Dauber JH, Yousem SA., 307(4):274–277.

Idiopathic Hypoparathyroidism Co-Existing With Celiac Disease: Immunologic Studies. Wortsman J, Kumar V., 307(6):420–427.

***Nocardia* Osteomyelitis.** Tokumoto JIN, Jacobs RA., 307(6):428–433.

The Anticardiolipin (Antibody) Syndrome. Merrick RD, Vernon M., 307(6):414–417.

The Lupus Anticoagulant-Hypoprothrombinemia Syndrome. Peacock NW, Levine SP., 307(5):346–349.

Transverse Myelitis Associated With Epstein-Barr Virus Infection. Caldas C, Bernicker E, Nogare AD, Luby JP., 307(1):45–48.

Use of Insulin-like Growth Factor-I Gene Expression to Distinguish Between Breast and Ovarian Cancer. Yee D, Jackson JG, Von Hoff DD, Ravdin PM., 307(2):108–111.

Wegener's Granulomatosis Accompanied by Communicating Hydrocephalus. Koga H, Oochi N, Osato S, Ishida I, Hirakata H, Okuda S, Fujishima M., 307(4):278–281.

Editorial

Should Intensive Care Be Limited for Patients With Self-Induced Disease? Terry PB, Fessler HE., 307(5):374–377.

Rapid Communication

Cationic Lipid Enhances in Vitro Receptor-Mediated Transfection. Mack KD, Walzem R, Zeldis JB., 307(2):138–143.

Endothelin A and B Receptors Are Down-Regulated in the Hearts of Hypertensive Rats. Hayzer DJ, Cicila G, Cockerham C, Griendling KK, Delafontaine P, Ng SC, Runge MS., 307(3):222–227.

High Plasma Concentrations of Cortisol and Thromboxane B_2 in Patients With Depression. Piccirillo G, Fimognari FL, Infantino V, Monteleone G, Fimognari GB, Falletti D, Marigliano V., 307(3):228–232.

Inhibition by Ethanol of the Cardiovascular Effects of Glutamate in the Nucleus of the Solitary Tract. Appalsamy M, Robertson D, Mosqueda-Garcia R., 307(2):133–137.

Seroreactivity and Genomic Amplification Profile of Hepatitis C Virus From Patients With Chronic Liver Disease in India. Khanna A, Naik SR, Thyagarajan SP, Talwar GP, Ray R., 307(2):144–150.

Reviews

Band 4.2 Abnormalities in Human Red Cells. Yawata Y., 307(3):190–203.

Celiac Disease: Clinical Features and Pathogenesis. Michalski JP, McCombs CC., 307(3):204–211.

Chenodeoxycholate: The Bile Acid. The Drug. A Review. Broughton G II., 307(1):54–63.

Clinical Use of Growth Factors in the Myelodysplastic Syndromes. Stein RS., 307(5):360–367.

Human Immunodeficiency Virus-Associated Nephropathy: Current Concepts. Stone HD, Appel RG., 307(3):212–217.

Ironic Catastrophes: One's Food—Another's Poison. Conrad ME, Uzel C, Berry M, Latour L., 307(6):434–437.

Long-term Oral Anticoagulant Therapy: Update on Indications, Therapeutic Ranges, and Monitoring. Raj G, Kumar R, McKinney WP., 307(2):128–132.

Mechanisms of Reperfusion Injury. Zimmerman BJ, Granger DN., 307(4):284–292.

Pathogenesis and Treatment of the Anemia of Chronic Disease. Krantz SB., 307(5):353–359.

Recent Advances in the Management of Gallstones. Gholson CF, Sittig K, McDonald JC., 307(4):293–304.

Significance of Glutathione in Lung Disease and Implications for Therapy. Morris PE, Bernard GR., 307(2):119–127.

Sotalol: A New Agent for the Treatment of Ventricular Arrhythmias. Samoil D, Grubb BP, Temesy-Armos PN., 307(1):49–53.

Tumor Drug-Resistance: A Challenge to Therapists and Biologists. Mansouri A, Henle KJ, Nagle WA., 307(6):438–444.

Southwestern Internal Medicine Conference

Brucellosis: Don't Let it Get Your Goat! Radolf JD., 307(1):64–75.

Clinical Applications of Transesophageal Echocardiography. Grayburn PA., 307(2):151–161.

Endothelial Dysfunction and Vascular Disease. Meidell RS., 307(5):378–389.

Pulmonary Complications of High-Altitude Exposure. Hsia CCW., 307(6):448–464.

Sarcoidosis: Immunology and Clinical Management. Weissler JC., 307(3):233–245.

The Syndrome of Angina Pectoris: Role of Visceral Pain Perception. Harford WV., 307(4):305–315.

Topics in Clinical Pharmacology

Pharmacologic Therapy for Human Immunodeficiency Virus Infection: A Review. Neuzil KM., 307(5):368–373.

Role of the Perfluorocarbon Fluosal-DA in Coronary Angioplasty. Kerins DM., 307(3):218–221.

Sumatriptan for Migraine. Charles PD, Davis TL., 307(6):445–447.

Key Indexing Terms

Absorption, 307(suppl 1):S116–S119.
Acanthosis nigricans, 307(5):342–345.
ACE inhibitors, 307(suppl 1):S81–S86, 307(suppl 1):S120–S125.

Acid-base balance, 307(suppl 1):S112–S115.
Actinomycosis, 307(6):418–419.
Acute ischemic heart disease, 307(1):21–26.
Adrenal disease, 307(2):112–114.
Afferent pathways, 307(4):305–315.
AIDS, 307(5):368–373.
Alcohol, 307(2):133–137, 307(6):391–395.
Alcohol abuse, 307(5):374–377.
Alpha-1 blocker, 307(suppl 1):S91–S95.
Altitude, 307(6):448–464.
Alveolar-capillary gas exchange, 307(6):448–464.
Alveolar macrophages, 307(6):408–413.
Ambulatory education, 307(1):36–39.
Amino acid(s), 307(2):97–101.
Amino acid receptors, 307(2):133–137.
Anatomy, 307(4):264–268.
Anemia, 307(3):190–203, 307(5):353–359, 307(6):405–407.
Angina pectoris, 307(4):305–315.
Angioplasty, 307(3):218–221.
Angiotensin, 307(suppl 1):S26–S37.
Angiotensin converting enzyme inhibitors, 307(suppl 1):S81–S86, 307(suppl 1):S120–S125.
Angiotensin-II receptor(s), 307(suppl 1):S26–S37.
Angiotensin-II receptor antagonists, 307(suppl 1):S26–S37.
Animal, 307(2):92–96.
Antiarrhythmic agents, 307(1):49–53.
Anticancer chemotherapy, 307(6):438–444.
Anticardiolipin antibody, 307(6):414–417.
Antihypertensive drugs, 307(suppl 1):S47–S52, 307(suppl 1):S120–S125.
Aorta, 307(6):408–413.
Aortic dissection, 307(2):151–161.
Arginine, 307(6):408–413.
Arrhythmia, 307(1):43–44, 307(1):49–53, 307(4):247–254, 307(4):259–263, 307(4):264–268.
Arterial system, 307(suppl 1):S3–S8.
Arthritis, 307(1):54–63.
Asialoglycoprotein, 307(2):138–143.
Atenolol, 307(4):259–263
Atherosclerosis, 307(3):228–232.
ATP, 307(suppl 1):S66–S69.
Atrial activity, 307(4):247–254.
Atrial fibrillation, 307(4):264–268.
Attitudes of medical students, 307(1):36–39.
Autoimmunity, 307(6):420–427.
Azygous vein blood flow, 307(6):396–400.
Beta adrenergic blockade, 307(6):396–400.
Beta adrenergic stimulation, 307(6):396–400.
Beta blockers, 307(5):317–324.
Beta-blockers, 307(1):49–53.
Bile acid, 307(1):54–63.
Biliary disease, 307(4):293–304.
Biological membranes, 307(suppl 1):S120–S125.
Blacks, 307(suppl 1):S38–S42.
Blood pressure, 307(suppl 1):S17–S20, 307(suppl 1):S87–S90, 307(suppl 1):S116–S119, 307(suppl 1):S138–S141, 307(3):173–181. *See also* Hypertension
Borderline hypertension, 307(suppl 1):S159–S162.
Brain angiotensin, 307(suppl 1):S26–S37.
Breast cancer, 307(2):108–111.
Bronchoalveolar lavage, 307(3):233–245.
Brucellosis, 307(1):64–75.
Calbindin, 307(suppl 1):S96–S101.
Calcitriol, 307(suppl 1):S154–S158.
Calcium, 307(suppl 1):S21–S25, 307(suppl 1):S60–S65, 307(suppl 1):S107–S111, 307(suppl 1):S116–S119, 307(suppl 1):S126–S129, 307(suppl 1):S138–S141. *See also* Hypercalcemia
Calcium, dietary, 307(suppl 1):S17–S20, 307(suppl 1):S130–S137.
Calcium, hypocalcemia, 307(6):420–427.
Calcium metabolism, 307(suppl 1):S102–S106.
Calcium nephrolithiasis, 307(suppl 1):S102–S106.
Calcium transport, 307(suppl 1):S96–S101.
Calmodulin, 307(suppl 1):S96–S101.
Calorimetry, 307(3):182–184.
Cancer, 307(2):108–111, 307(5):350–352, 307(6):438–444, 307(6):418–419.
Candida, 307(2):115–118.
Candidiasis, 307(4):282–283.
Capillary occlusion, 307(2):86–91.
Cardiac output, 307(2):92–96.
Cardioverter, 307(3):185–189.
Career choice, 307(1):36–39.
Castleman disease, 307(2):112–114.
Cationic lipid, 307(2):138–143.
Cation transports, 307(suppl 1):S146–S149.
Celiac disease, 307(3):204–211, 307(6):420–427.
Cell injury, 307(4):284–292.
Cerebrotendinous xanthomatosis, 307(1):54–63.
Chemodeoxycholate, 307(1):54–63.
Chemotherapy, 307(6):438–444.
Cholecystectomy endoscopic retrograde cholangiopancreatography, 307(4):293–304.
Cholesterol, 307(4):269–273.
Chronic disease, 307(5):353–359.
Chronic mucocutaneous candidiasis, 307(4):282–283.
Cigarette smoking, 307(suppl 1):S150–S153, 307(5):374–377.
Circulatory collapse, 307(4):284–292.
Claims data, 307(5):329–334.
Clinical skills training, 307(3):163–166.
Clinicopathologic correlations, 307(3):212–217.
Clot retraction, 307(1):15–20.
C-myc, 307(3):167–172.
Complication, 307(4):278–281.
Computed tomography, 307(6):418–419.
Constipation, 307(1):54–63.
Cortisol, 307(3):228–232.
Creatinine clearance, 307(2):97–101.
Cysteine, 307(2):119–127.
Cystic fibrosis, 307(2):82–85.
Cytotoxicity, 307(6):391–395.
Defibrillator, 307(3):185–189.
Deformability, 307(2):86–91.
Depression, 307(3):228–232.
Diabetes mellitus, 307(suppl 1):S53–S59, 307(suppl 1):S60–S65, 307(suppl 1):S66–S69, 307(suppl 1):S75–S80, 307(suppl 1):S142–S145.
Diastolic function, 307(2):92–96.
Didanosine, 307(5):368–373.
Diet, 307(4):269–273, 307(6):420–427. *See also* Nutrition
Dietary calcium, 307(suppl 1):S17–S20, 307(suppl 1):S130–S137.
Dietary salt, 307(suppl 1):S87–S90.
Dietary treatment, 307(3):204–211.
Digoxin-like immunoreactivity, 307(1):27–35.
Distal tubule, 307(suppl 1):S53–S59.
Diuretics, 307(suppl 1):S120–S125.
2, 3 DPG, 307(suppl 1):S66–S69.
Drug abuse, 307(5):374–377. *See also* Alcohol
Drug-resistant tumor cells, 307(6):438–444.
Echocardiography, 307(2):151–161, 307(4):264–268.
Education, ambulatory, 307(1):36–39.
Education, medical students, 307(3):163–166.
Eggwhite, 307(5):335–339.
Eicosanoids, 307(3):173–181.
Elastic modulus, 307(1):15–20.
Elderly, 307(1):40–42.
Enalapril, 307(suppl 1):S150–S153.
Endocardial catheter mapping, 307(4):247–254.
Endocarditis, 307(2):151–161.
Endocrinopathy, 307(2):112–114.
Endoscopic retrograde cholangiopancreatography, 307(4):293–304.
Endothelium, 307(1):7–14, 307(5):378–389.
Enteropathy, gluten sensitive, 307(3):204–211.
Enzyme-immunoassays, 307(2):144–150.
Enzyme kinetics, 307(1):27–35.
Epidemiology, 307(suppl 1):S17–S20.
Epstein-Barr virus, 307(1):45–48.
Erythrocytes, 307(suppl 1):S43–S46, 307(suppl 1):S66–S69, 307(suppl 1):S120–S125, 307(suppl 1):S146–S149, 307(3):190–203, 307(5):353–359.
Erythropoietic protoporphyria, 307(1):54–63.
Erythropoietin, 307(5):360–367.
Escherichia coli, 307(5):335–339.
Esmolol, 307(4):259–263
Esophageal motility disorders, 307(4):305–315.
Essential hypertension, 307(suppl 1):S43–S46, 307(suppl 1):S47–S52, 307(suppl 1):S70–S74.
Ethanol, 307(2):133–137, 307(5):374–377, 307(6):391–395.
Ethics, 307(3):212–217.
Excitatory amino acid receptors, 307(2):133–137.
Exosurf, 307(6):401–404.
EXP 3174, 307(suppl 1):S26–S37.
FAA, 307(4):247–254.
F-actin, 307(2):86–91.
False positive VRDL, 307(6):414–417.
Familial candidiasis, 307(4):282–283.
Fibrinogen, 307(5):317–324.
Fibrinolysis, 307(5):317–324.
Fibrin structure, 307(1):15–20.
Fibrosis, mediastinal, 307(4):274–277.
Fluconazole, 307(4):274–277.
Fluosol, 307(3):218–221.
Fragmented atrial activity, 307(4):247–254.
Fungemia, 307(2):115–118.

Gallstones, 307(1):54–63.
Gas exchange, 307(6):448–464.
Gastroesophageal reflux, 307(4):305–315.
G-CSF, 307(5):360–367.
Gender, 307(5):317–324.
Gene expression, 307(2):77–81, 307(3):173–181.
Gene therapy, 307(2):138–143, 307(5):378–389.
Genome amplification, 307(2):144–150.
Gliadin, 307(3):204–211.
Glucose, 307(suppl 1):S60–S65, 307(5):342–345.
Glucose metabolism, 307(suppl 1):S91–S95.
Glucose tolerance, 307(suppl 1):S47–S52.
Glutamate, 307(2):133–137.
Glutathione, 307(2):119–127.
Gluten, 307(3):204–211.
Gluten-free diet, 307(6):420–427.
Gluten sensitive enteropathy, 307(3):204–211.
GM-CSF, 307(5):360–367.
Granulocyte, 307(2):86–91.
Granulocyte colony-stimulating factors, 307(5):360–367.
Granulocyte-macrophage colony-stimulating factors, 307(5):360–367.
Granuloma, 307(3):233–245.
Granuloma, mediastinal, 307(4):274–277.
Growth, 307(6):405–407.
Growth factors, 307(suppl 1):S9–S16, 307(2):77–81, 307(2):108–111.
Headache, 307(6):445–447.
Hearing loss, 307(1):40–42.
Heart disease, 307(1):21–26, 307(2):151–161.
Heart disease, ischemic, 307(1):21–26.
Heart ventricle, 307(2):92–96.
Hematogenous dissemination, 307(6):418–419.
Hemodynamics, 307(suppl 1):S142–S145.
Hemolytic anemia, 307(3):190–203.
Hepatitis C virus, 307(2):144–150.
High altitude, 307(6):448–464.
Histoplasma capsulatum, 307(4):274–277.
HLA class II, 307(3):204–211.
^{3}H-ouabain displacement, 307(1):27–35.
Human immunodeficiency virus, 307(3):212–217, 307(5):368–373.
Human red cells, 307(3):190–203.
Humoral hypercalcemia of malignancy, 307(5):350–352.
Hydrocephalus, 307(4):278–281.
Hypercalcemia, 307(1):43–44, 307(5):350–352, 307(6):420–427.
Hypercoagulable state, 307(6):414–417.
Hyperkalemia, 307(suppl 1):S81–S86, 307(4):255–258.
Hyperlipidemia, 307(4):269–273.
Hyperphosphatemia, 307(4):255–258.
Hypertension, 307(suppl 1):S3–S8, 307(suppl 1):S21–S25, 307(suppl 1):S26–S37, 307(suppl 1):S38–S42, 307(suppl 1):S53–S59, 307(suppl 1):S60–S65, 307(suppl 1):S66–S69, 307(suppl 1):S75–S80, 307(suppl 1):S91–S95, 307(suppl 1):S96–S101, 307(suppl 1):S102–S106, 307(suppl 1):S107–S111, 307(suppl 1):S112–S115, 307(suppl 1):S120–S125, 307(suppl 1):S126–S129, 307(suppl 1):S130–S137, 307(suppl 1):S142–S145, 307(suppl 1):S150–S153, 307(suppl 1):S154–S158, 307(3):222–227, 307(5):317–324.
Hypertension, borderline, 307(suppl 1):S159–S162.
Hypertension, essential, 307(suppl 1):S43–S46, 307(suppl 1):S47–S52, 307(suppl 1):S70–S74.
Hypertension, portal, 307(6):396–400.
Hypertensive therapy, 307(suppl 1):S47–S52, 307(suppl 1):S120–S125.
Hypocalcemia, 307(6):420–427.
Hypoparathyroidism, 307(6):420–427.
Hypoprothrombinemia, 307(5):346–349.
Hypothalamus, 307(3):228–232.
Hypoxemia, 307(6):448–464.
Hypoxic tissues, 307(4):284–292.
Implantable cardioverter-defibrillator, 307(3):185–189.
Infection, 307(1):64–75.
Infection, post-operative, 307(6):428–433.
Infection, renal, 307(5):335–339.
Infusion, 307(suppl 1):S154–S158.
Injection, 307(suppl 1):S154–S158. *See also* Microinjections
INR, 307(2):128–132.
Insulin, 307(suppl 1):S43–S46, 307(1):21–26.
Insulin-dependent diabetes, 307(suppl 1):S43–S46.
Insulin-like growth factor binding proteins, 307(2):77–81.
Insulin-like growth factor I, 307(2):77–81, 307(2):108–111.
Insulin-like growth factor II, 307(2):108–111.
Insulin resistance, 307(suppl 1):S47–S52, 307(suppl 1):S75–S80, 307(5):342–345.
Intensive care, 307(5):374–377.
Interleukin-2, 307(6):391–395.
Interventions, 307(suppl 1):S17–S20.
Intestine, 307(suppl 1):S116–S119.
Intracellular pH, 307(suppl 1):S9–S16.
Intrathoracic disease, 307(2):112–114.
Ions, 307(suppl 1):S126–S129.
Ion transport, 307(suppl 1):S120–S125.
Iron-binding proteins, 307(2):102–107.
Iron deficiency, 307(6):434–437.
Iron excess, 307(6):434–437.
Ischemia, 307(suppl 1):S66–S69, 307(3):218–221, 307(4):284–292.
Ischemic heart disease, 307(1):21–26.
Kidney, 307(suppl 1):S53–S59.
Kidney disease, 307)3):212–217.
Kidney function, 307(suppl 1):S107–S111.
Kidney infection, 307(5):335–339.
Kinetics, 307(suppl 1):S38–S42.
Laboratory abnormalities, 307(4):255–258.
Lactoferrin, 307(2):102–107.
Li^+/Na^+ countertransport, 307(suppl 1):S43–S46, 307(suppl 1):S53–S59.
Lipid(s), 307(suppl 1):S146–S149, 307(suppl 1):S150–S153, 307(2):138–143, 307(4):269–273, 307(5):317–324.
Lipid metabolism, 307(suppl 1):S91–S95.
Liver regeneration, 307(3):167–172.
Long-term terazosin therapy, 307(suppl 1):S91–S95.
Losartan, 307(suppl 1):S26–S37.
Lung injury, 307(2):119–127.
Lupus anticoagulant, 307(5):346–349, 307(6):414–417.
Lupus anticoagulant-hypoprothrombinemia syndrome, 307(5):346–349.
Lymphadenopathy, 307(2):112–114.
Lymphocytes, 307(suppl 1):S159–S162, 307(2):102–107.
Lymphokine-activated killer cell, 307(6):391–395.
Lymphoma, 307(3):204–211.
Macrophages, 307(1):1–6.
Macrophages, alveolar, 307(6):408–413.
Magnesium, 307(suppl 1):S17–S20.
Meal frequency, 307(2):97–101.
Mediastinal fibrosis, 307(4):274–277.
Mediastinal granuloma, 307(4):274–277.
Medical student attitudes, 307(1):36–39.
Medical student education, 307(3):163–166.
Membrane protein band 3, 307(3):190–203.
Membrane protein band 4.2, 307(3):190–203.
Meningitis, 307(2):115–118, 307(4):282–283.
Metaanalysis, 307(suppl 1):S130–S137.
Metabolism, 307(suppl 1):S112–S115.
Mice, 307(5):335–339.
Microinjections, 307(suppl 1):S26–S37, 307(2):133–137.
Midwestern United States, 307(2):82–85.
Migraine headache, 307(6):445–447.
Mithramycin, 307(3):167–172.
Monocytes, 307(2):102–107.
Multifocal atrial tachycardia, 307(4):264–268.
Mutational patterns, 307(2):82–85.
Myelitis, 307(1):45–48.
Myelodysplastic syndromes, 307(5):360–367.
Myocardial function, 307(2):92–96.
Myocardial scar, 307(4):259–263
NaCl sensitive hypertension. *See* Salt sensitivity
Na^+/H^+ exchange, 307(suppl 1):S9–S16, 307(suppl 1):S43–S46, 307(suppl 1):S53–S59, 307(suppl 1):S112–S115, 307(suppl 1):S159–S162.
Na-K-ATPase, 307(suppl 1):S53–S59, 307(1):27–35.
Na^+/Li^+ exchange, 307(suppl 1):S43–S46, 307(suppl 1):S53–S59.
Natriuresis, 307(3):173–181.
Natural killer cell, 307(6):391–395.
Necrosis, 307(4):284–292.
Neonatal respiratory distress syndrome, 307(6):401–404.
Nephritis, 307(1):1–6.
Nifedipine, 307(suppl 1):S150–S153.
Nitric oxide, 307(1):7–14.
NMR spectroscopy, 307(suppl 1):S60–S65, 307(suppl 1):S66–S69.
Nocardia, 307(6):428–433.
Nociceptors, 307(4):305–315.
Nodules, 307(6):418–419.
Norepinephrine, 307(suppl 1):S138–S141.
Normochromic, normocytic anemia, 307(5):353–359.
Nuclear runoff, 307(3):173–181.
Nucleus of the solitary tract, 307(2):133–137.
Nutrition, 307(2):97–101, 307(6):405–407, 307(6):434–437. *See also* Diet
Nutritional deficiencies, 307(3):204–211.

Obesity, 307(suppl 1):S75–S80, 307(5):325–328.
Obesity recidivism, 307(5):325–328.
Obesity treatment, 307(5):325–328.
Oral anticoagulants, 307(2):128–132.
Osmotic pumps, 307(suppl 1):S154–S158.
Osteomyelitis, 307(6):428–433.
Outcomes research, 307(5):329–334.
Ovarian cancer, 307(2):108–111.
Pancreatic hormones, 307(5):342–345.
Paraneoplastic syndrome, 307(5):350–352.
Parathyroid, 307(suppl 1):S126–S129.
Parathyroid hormone-related protein, 307(5):350–352.
Perioperative complications, 307(3):185–189.
P fimbriated *Escherichia coli*, 307(5):335–339.
PGE_1, 307(1):21–26.
PGI_2, 307(1):21–26.
Pharmacokinetics, 307(suppl 1):S38–S42.
Pharmacology, 307(5):368–373.
Plasma renin activity, 307(suppl 1):S159–S162.
Plasminogen activator inhibitor, 307(5):317–324.
Platelet(s), 307(1):21–26, 307(5):340–341.
Platelet function, 307(1):15–20.
POEMS, 307(2):112–114.
Polylysine, 307(2):138–143.
Portal hypertension, 307(6):396–400.
Post-operative infection, 307(6):428–433.
Potassium, 307(suppl 1):S17–S20, 307(suppl 1):S21–S25, 307(suppl 1):S107–S111.
Potassium, hyperkalemia, 307(suppl 1):S81–S86, 307(4):255–258.
PRA, 307(suppl 1):S159–S162.
Practical skills, 307(3):163–166.
Pre-contracted aorta, 307(6):408–413.
Prehypertensive stage, 307(suppl 1):S70–S74.
Prostacyclin I_2, 307(1):21–26.
Prostaglandin E_1, 307(1):21–26.
Protease inhibitors, 307(5):368–373.
Protein inhibition, 307(6):401–404.
Prothrombin-antiprothrombin antibody complexes, 307(5):346–349.
Protoporphyria, erythropoietic, 307(1):54–63.
Proximal tubule, 307(suppl 1):S53–S59.
Psychophysiology, 307(suppl 1):S142–S145.
Psychosocial factors, 307(3):228–232.
Psyllium, 307(4):269–273.
Pulmonary surfactant, 307(6):401–404.
Quality assessment and improvement, 307(5):329–334.
Quality assurance, 307(5):329–334.
Racial differences, 307(suppl 1):S38–S42.
RAF, 307(4):247–254.
Rats, 307(suppl 1):S116–S119, 307(1):7–14, 307(2):92–96, 307(3):222–227, 307(6):408–413. *See also* Salt-hypertensive rats; Wistar-Kyoto rats
Reactive oxygen species, 307(2):119–127.
Receptor(s), 307(suppl 1):S26–S37, 307(1):21–26, 307(2):133–137.
Receptor-mediated transfection, 307(2):138–143.
Relaxation, 307(1):7–14.
Renal disease, 307(3):212–217.
Renal dopamine, 307(suppl 1):S70–S74.
Renal function, 307(suppl 1):S107–S111.
Renal infection, 307(5):335–339.
Renal kallikrein-kinin, 307(suppl 1):S70–S74.
Renal prostaglandin E_2, 307(suppl 1):S70–S74.
Reperfusion injury, 307(4):284–292.
Repetitive atrial firing, 307(4):247–254.
Resistance artery, 307(1):7–14.
Respiratory distress, 307(4):284–292.
Respiratory distress syndrome, 307(3):182–184, 307(6):401–404.
Reticulocytes, 307(5):353–359.
Retinopathy, 307(2):86–91.
Rheumatoid arthritis, 307(1):54–63.
Salt, 307(suppl 1):S38–S42, 307(suppl 1):S87–S90, 307(suppl 1):S138–S141. *See also* Salt senitivity; Sodium
Salt-hypertensive sensitive rats, 307(3):222–227.
Salt sensitivity, 307(suppl 1):S26–S37, 307(suppl 1):S38–S42, 307(suppl 1):S75–S80, 307(suppl 1):S112–S115, 307(suppl 1):S130–S137.
Screening, 307(1):40–42.
Self-induced disease, 307(5):374–377.
Sepsis, 307(5):340–341.
Serotonin agonist, 307(6):445–447.
Serum lipids, 307(suppl 1):S87–S90.
SHR. *See* Spontaneously hypertensive rats
Sickle cell anemia, 307(6):405–407.
Sick sinus syndrome, 307(4):247–254.
Smoking, 307(suppl 1):S150–S153, 307(5):374–377.
Sodium, 307(suppl 1):S3–S8, 307(suppl 1):S17–S20, 307(suppl 1):S21–S25, 307(suppl 1):S38–S42, 307(suppl 1):S107–S111. *See also* Na^+/H^+ exchange; Na^+/Li^+ exchange; salt; Salt sensitivity
Sodium-potassium-activated adenosine-triphosphatase inhibitor, 307(1):27–35.
Soluble fiber, 307(4):269–273.
Sotalol, 307(1):49–53.
Spontaneously hypertensive rat, 307(suppl 1):S154–S158, 307(1):7–14.
Spontaneously hypertensive rats, 307(suppl 1):S96–S101, 307(suppl 1):S130–S137, 307(suppl 1):S138–S141, 307(3):222–227.
Statistical process control, 307(5):329–334.
Stress, 307(suppl 1):S130–S137, 307(suppl 1):S142–S145.
Stroke, 307(2):151–161.
Stroke volume, 307(2):92–96.
Substance abuse, 307(5):374–377. *See also* Alcohol
Sumatriptan, 307(6):445–447.
Survanta, 307(6):401–404.
Sympathetic nervous system, 307(suppl 1):S150–S153.
Systemic vasculitis, 307(4):278–281.
Tat inhibitors, 307(5):368–373.
T cell, 307(3):233–245.
Terazosin therapy, 307(suppl 1):S91–S95.
TGFβ1, 307(1):1–6.
Therapy, 307(5):368–373.
Thrombocytosis, 307(4):255–258.
Thromboembolic disease, 307(6):414–417.
Thrombosis, 307(5):346–349.
Thromboxane, 307(3):228–232.
Thyroid disease, 307(2):112–114.
Tissue oxygenation, 307(4):284–292.
Tobacco, 307(suppl 1):S150–S153, 307(5):374–377.
Transesophageal echocardiography, 307(2):151–161.
Transfection, 307(2):138–143.
Transforming growth factor alpha, 307(2):108–111.
Transfusion, 307(5):340–341.
Transverse myelitis, 307(1):45–48.
Triglyceride, 307(5):317–324.
Tumor drug-resistance, 307(6):438–444.
Valvular heart disease, 307(2):151–161.
Vascular disease, 307(5):378–389.
Vascular endothelial cells, 307(5):378–389
Vascular reactivity, 307(suppl 1):S138–S141, 307(suppl 1):S154–S158.
Vascular smooth muscle, 307(suppl 1):S9–S16.
Vasculitis, systemic, 307(4):278–281.
Vasoconstrictors, 307(suppl 1):S9–S16.
Ventilatory control, 307(6):448–464.
Ventricular function, 307(4):259–263
VRDL, 307(6):414–417.
Warfarin, 307(2):128–132.
Wegener's granulomatosis, 307(4):278–281.
Whites, 307(suppl 1):S38–S42.
Wistar Kyoto rats (WKR), 307(suppl 1):S96–S101, 307(1):7–14, 307(3):222–227.
Women, 307(4):269–273.
Xanthomatosis, cerebrotendinous, 307(1):54–63.
Zalcitabine, 307(5):368–373.
Zidovudine, 307(5):368–373.